Trinity Biotech

Trinity Biotech Debt / Assets

The Debt-to-Assets Ratio of Trinity Biotech (TRIB) as of Oct 16, 2026 is 1.31. In the previous year, Debt-to-Assets Ratio was 0.98 — a change of 34.50% (higher).

Debt / Assets

1.31

YoY

34.50%

Last updated:

Debt-to-Assets Ratio of Trinity Biotech is 2025 1.31 . Debt-to-Assets Ratio of Trinity Biotech was 2024 0.98 . It decreases by 34.50% higher compared to the previous year.

The Trinity Biotech Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2018
0.54 USD
Jan 1, 2019
0.78 USD
Jan 1, 2020
0.80 USD
Jan 1, 2021
0.83 USD
Jan 1, 2022
0.78 USD
Jan 1, 2023
1.13 USD
Jan 1, 2024
0.98 USD
Jan 1, 2025
1.31 USD
The Trinity Biotech Debt / Assets history
YEARDebt / AssetsYoY
1.31+34.50%
0.98-14.01%
1.13+44.72%
0.78-6.01%
0.83+4.23%
0.80+2.65%
0.78+43.67%
0.54+9.80%
0.49+27.46%
0.39+41.94%
0.27+370.51%
0.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Debt-to-Assets Ratio of Trinity Biotech is 1.31 in 2025.

Debt-to-Assets Ratio of Trinity Biotech changed from 0.98 to 1.31, representing a 34.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Trinity Biotech

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Trinity Biotech